Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL336363 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL336362 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL13517377 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL5019049 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL2553076 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL336361 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL1130719 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL12648656 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL16237980 | 0.97 | TSHR (0.53) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL8200338 | 0.97 | TSHR (0.53) | TSHRSLC7A5USP2SLCO1B1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2004670-A1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AiCuris GmbH & Co. KG (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007118693-A1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | TSHR 829/4885SLC7A5 298/4885USP2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.